Fax: (404) 778-5152
Comparing central nervous system (CNS) and extra-CNS hemangiopericytomas in the Surveillance, Epidemiology, and End Results program
Analysis of 655 patients and review of current literature
Article first published online: 19 APR 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 21, pages 5331–5338, 1 November 2012
How to Cite
Hall, W. A., Ali, A. N., Gullett, N., Crocker, I., Landry, J. C., Shu, H.-K., Prabhu, R. and Curran, W. (2012), Comparing central nervous system (CNS) and extra-CNS hemangiopericytomas in the Surveillance, Epidemiology, and End Results program. Cancer, 118: 5331–5338. doi: 10.1002/cncr.27511
- Issue published online: 19 OCT 2012
- Article first published online: 19 APR 2012
- Manuscript Accepted: 1 FEB 2012
- Manuscript Revised: 5 JAN 2012
- Manuscript Received: 12 AUG 2011
- central nervous system (CNS);
- extra-CNS hemangiopericytoma;
- End Results database;
- radiation therapy
Hemangiopericytomas (HPCs) are rare tumors in the central nervous system (CNS) and in extra-CNS sites. The authors of this report used the Surveillance, Epidemiology, and End Results (SEER) Program to study prognostic factors in patients with HPC.
The SEER database was analyzed for patients who were diagnosed with HPC tumors from 1973 to 2007. Patients were stratified into CNS and extra-CNS groups. Univariate and multivariate analyses were performed for the overall survival (OS) endpoint using major demographic factors (age, race, and sex) and disease factors (tumor site).
In total, 655 patients with HPC were stratified into a CNS group (n = 199) and an extra-CNS group (n = 456). The patients with extra-CNS HPC were statistically older (mean age, 53 years vs 49 years; P = .008) and were more likely to have larger tumors (median greatest dimension, 7.0 cm vs 5.2 cm; P < .001). Patients who had CNS tumors had better OS and cause-specific survival (CSS) compared with patients who had extra-CNS tumors (P < .001 for both). Negative predictors of OS on multivariate analysis included extra-CNS tumor site (hazard ratio [HR], 1.6; P = .005) and older age (ages 40-59 years: HR, 2.08; P = .032; ages 60-79 years: HR, 3.9; P < .001; aged ≥80 years: HR, 7.7; P < .001).
The current analysis demonstrated that patients with extra-CNS HPCs had worse OS and CSS than patients with CNS HPCs. Cancer 2012. © 2012 American Cancer Society.